TCW Group’s Viking Therapeutics VKTX Stock Holding History

TCW Group’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-45,322	Closed	-$1.2M	–	351
2025 Q2	$1.2M	Sell	45,322 -29,732	-40%	-$783K	0.01%	294
2025 Q1	$1.81M	Buy	75,054 +13,403	+22%	+$424K	0.02%	261
2024 Q4	$2.48M	Buy	+61,651	New	+$3.52M	0.02%	241

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCW Group's VKTX Position: Q3 2025 in Review

TCW Group sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 45,322 shares — an estimated $1.2M sold.

TCW Group first reported a position in VKTX in Q4 2024 and held it in 3 quarters. The position peaked at $2.48M in Q4 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

TCW Group reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
TCW Group sold 45,322 Viking Therapeutics shares in Q3 2025, an estimated $1.2M.
TCW Group first reported a position in Viking Therapeutics in Q4 2024 and held it in 3 quarters.
TCW Group's Viking Therapeutics position peaked at $2.48M in Q4 2024.
370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on TCW Group's 13F filing for Q3 2025, filed 14 Nov 2025.